Biotech Daily

Monday July 6, 2026

Daily news on ASX-listed biotechnology companies

*** ASX DOWN, BIOTECH UP: PRESCIENT UP 22%; PROTEOMICS DOWN 12.5%**

*** BRANDON: NOVARTIS TO PAY $2.2b FOR MYRICX BIO, 20% HOLDER**

*** CYNATA CUTS STAFF, EVALUATION**

*** COMPUMEDICS: 'REVENUE UP 18% TO $60m; BELOW GUIDANCE'**

*** NEXALIS LOSES $53m POINT8 LOAN**

*** SYNTARA: 'SNT-4728 SIGNIFICANTLY REDUCES BRAIN INFLAMMATION'**

*** ONCOSIL 'MORE TRIPP-FFX DATA BACKS PRIMARY ENDPOINTS'**

*** HUDSON: 'REMOVING NLPR3 PROTEIN REDUCES SILICOSIS, IN MICE'**

*** RENERVE INDONESIA NERVALIGN APPROVAL**

*** NYRADA DOSES 1st PHASE IIa NYR-BI03 CARDIAC PATIENT**

*** IMMURON APPOINTS PULLAN FOR IMM-529 C. DIFFICILE PARTNERS**

*** CONTROL BIONICS 1.25m DIRECTOR OPTIONS EGM**

*** RADIOPHARM RECEIVES $5.9m FEDERAL R&D TAX INCENTIVE**

*** PROTEOMICS PLEADS 'SCHULTZ, END OF YEAR' TO 37.5% PRICE QUERY**

*** CURVEBEAM REQUESTS 'CAPITAL RAISING' TRADING HALT**

*** PHOENIX DILUTED TO 16% OF CONTROL BIONICS**

*** AMPLIA APPOINTS MDGH'S BRETT CARTER DIRECTOR**

*** COMPUMEDICS LOSES 9-MONTH DIRECTOR CHRISTOPHER BARYS**

*** CHIMERIC LOSES DIRECTOR ERIC SULLIVAN**

MARKET REPORT

The Australian stock market fell 0.15 percent on Monday July 6, 2026, with the ASX200 down 13.4 points to 8,831.0 points.

Seventeen of the Biotech Daily Top 40 companies were up, 11 fell, 10 traded unchanged and two were untraded. All four Big Caps were up.

Prescient was the best, up 1.5 cents or 22.1 percent to 8.3 cents, with 2.2 million shares traded. Clarity climbed 19.0 percent; Compumedics was up 12.5 percent; Orthocell rose 9.9 percent; Dimerix was up 8.3 percent; Resonance rose 6.8 percent; Botanix and Syntara were up more than four percent; Telix was up 3.0 percent; 4D Medical, Cochlear, CSL, Medical Developments, Nanosonics and Pro Medicus rose two percent or more; Actinogen, Mesoblast, Polynovo, Resmed and Saluda were up one percent or more; with Racura up by 0.9 percent.

Proteomics led the falls, down 2.5 cents or 12.5 percent to 17.5 cents, with 2.45 million shares traded. EBR lost 5.75 percent; Cyclopharm fell 4.0 percent; Alcidion shed 2.0 percent; Artrya and Starpharma were down more than one percent; with Aroa, Clinuvel, Emvision, Imricor and Neuren down by less than one percent.

BRANDON CAPITAL

Brandon Capital says that Basel, Switzerland's Novartis AG will buy London, England's Myricx Bio for $2.16 billion, of which Brandon is entitled to about 20 percent.

A media release from Brandon Capital said that Novartis AG would buy Myricx Bio and its pre-clinical antibody-drug conjugates (ADCs) for use in oncology, including $1.58 billion up-front plus potential milestone payments.

The company said that the acquisition of London's Myricx Bio was "one of the largest upfront cash payments for an early-stage pre-clinical biotechnology company".

Brandon Capital said that it was a joint founding seed investor in Myricx Bio in 2019 and had "played an instrumental role in the formation" of the company; and managing partner Dr Stephen Thompson led the investment from initial seed funding to the exit.

The company said that Myricx Bio was a spin-out company from Imperial College London and the Francis Crick Institute.

Brandon Capital said Myricx was co-founded by Brandon Capital Venture partner Dr Roberto Solari who served as Myricx Bio's founding chief executive officer.

The company said that Myricx Bio was developing "a new class of payloads" for … ADCs, aimed at addressing toxicity challenges associated with current treatments".

Brandon Capital said that ADCs were targeted cancer therapies that used antibodies "to deliver chemotherapy directly to tumor cells while limiting damage to healthy tissue, making them one of the fastest-growing areas in oncology".

The company said the exit would "generate a significant return for Brandon Capital's investors" including Australian superannuation funds Hostplus, Health Employees Superannuation Trust Australia (HESTA) and Aware Super as well as CSL and Queensland Investment Corporation (QIC).

Brandon Capital said UK-based partner Dr Jonathan Tobin joined Myricx Bio as an executive director in 2023 and was a co-inventor on one of Myricx Bio's antibody-drug conjugate patents alongside Dr Solari and Myricx Bio chief scientific officer Dr Francesca Zammarchi.

CYNATA THERAPEUTICS

Cynata says following two negative trial results all employees, including managing-director Dr Kilian Kelly, will be made redundant, with a reduced board to evaluate future options.
Last month, Cynata fell 94.2 percent on its phase II trial of CYP-001 for acute graft versus host disease and its phase III CYP-004 for knee osteo-arthritis trials showing "no significant differences" between active and control groups (BD: Jun 17, 19, 2026).
Today, the company said it would make all employees redundant, director Dr Darryl Maher had resigned, and Dr Kelly would continue as a non-executive director without remuneration, with all other directors agreeing to waive their fees.
Cynata said it suspended or terminated outsourced activities "to the maximum extent possible, whilst preserving the company's intellectual property" and it had a $600,000 loan secured against its expected $1.7 million Federal Government Research and Development Tax Incentive for the year to June 30, 2026.
Cynata said with cost-cutting measures it expected its cash burn to be reduced to about $2.3 million for 2026-'27, including employee termination payments of about $700,000 and close-out costs for the graft versus host disease trial of $1,100,000.
The company said the remainder of expenditure was the cost of maintaining intellectual property rights, storage of product, regulatory obligations and corporate costs.
Cynata said its board was "continuing to evaluate a number of options for further development of the Cymerus technology and for next steps for the company".
Cynata chair Dr Geoff Brooke said it was "an extremely difficult period for the company and its shareholders, and … the impact this has had on all our stakeholders".
Cynata was up 0.3 cents or 23.1 percent to 1.6 cents with 10.1 million shares traded.

COMPUMEDICS

Compumedics says it expects shipped and invoiced revenue for the year to June 30, 2026 up 18.3 percent to about $60.3 million, "modestly below" its April 2026 guidance.
Last year, Compumedics said revenue for the year to June 30, 2025 rose 2.5 percent to a record $50,957,000, with net loss after tax of $1,272,000 (BD: Aug 27, 2025).
Earlier this year, the company said it expected revenue for the year to June 30, 2026 to be up 22 percent to 28 percent to between $62 million and $65 million, compared to the prior year, and earnings before interest, taxation, depreciation and amortization (Ebitda) of about $5.5 million to $7 million for the year (BD: Apr 21, 2026).
Today, Compumedics said it expected to report sales orders of about $62.7 million for the year to June 30, 2026, "reflecting continued demand across its global sleep, neurology, magneto-encephalography (MEG) and connected platform business".
The company said the result showed "continued operating progress, with strong year-on-year growth in shipped and invoiced revenue, and a growing contribution from recurring [software-as-a-service] revenues".
Compumedics said earnings before interest, taxation, depreciation and amortization (Ebitda) was expected to increase, subject to audit, reflecting "the benefit of higher shipped and invoiced revenue, cost discipline across the group and the increasing contribution from connected and recurring revenue platforms".
The company said its reduced expectations primarily reflected "timing factors, including further delays to MEG shipment and invoicing caused by higher helium prices from the conflict in the Middle East, which are now resolved, together with Somfit D continuing to move cautiously toward commercial release in the US".
Compumedics said it was targeting "further double-digit revenue growth in 2026-'27".
Compumedics was up three cents or 12.5 percent to 27 cents.

NEXALIS THERAPEUTICS (FORMERLY INHALERX)

Nexalis says negotiations with Sydney's Point8 Capital Pty Ltd have ceased after it was "unable to progress the process to a formal funding agreement".
In May, Nexalis said an up-to $53 million Point8 loan at 15 percent a year interest secured against assets and undertakings would replace a previous loan (BD: May 28, 2026).
At the time, the company said the loan would fund inhaled marijuana trials, and would replace last year's Linlithgow Family Office loan (BD: Dec 4, 2025)
Today, Nexalis said it was assessing development priorities "with a view to determining a revised clinical development plan and timeline for its portfolio of drug candidates".
The company said it had $490,000 form a Federal Government Research & Development Tax Incentive following lodgement of its 2025 income tax return.
Nexalis said it was "unable to progress negotiations to a formal agreement … [and would] continue to work towards identifying and securing suitable alternative funding solutions, [but] there are … no meaningful discussions underway".
Nexalis said it had requested $2,400,000 from the Linlithgow facility, with $800,000 received and it was "firmly of the view that [Linlithgow] is obliged to honor the $1.6 million of eligible funding requests" outstanding when the facility was withdrawn.
Nexalis was unchanged at one cent with 3.4 million shares traded.

SYNTARA

Syntara says SNT-4728 for isolated REM sleep behavior disorders shows "a statistically significant reduction in brain inflammation unilaterally in the putamen ($p = 0.0145$)".
Syntara said the preliminary analyses of its 41-patient, phase II study of SNT-4728 for isolated rapid eye movement (REM) sleep behavior disorder, a disorder associated with a high-risk of progression to Parkinson's disease and related diseases.
The company said the first tranche of data from the randomized, double-blind, placebo-controlled phase II trial "provided encouraging signs of reduced brain inflammation".
Syntara said positron emission tomography (PET) imaging using the translocator protein (TSPO) was used to monitor the activation of microglia in addition to the measurement of other markers of neuro-inflammation in the brain.
The company said the trial showed "a statistically significant reduction in brain inflammation unilaterally in the putamen ($p = 0.0145$), with 20 of 30 patients receiving SNT-4728 demonstrating a reduction from baseline".
Syntara said the putamen was associated with Parkinson's motor symptoms, including bradykinesia, rigidity, tremor, and was linked to non-motor features such as motivation.
The company said no statistically significant change in inflammation was detected in other pre-defined regions of interest such as substantia nigra, caudate and occipital cortex.
Syntara said broader analyses "further validated the anti-inflammatory effect of SNT-4728 by identifying additional areas of statistically significant reduced TSPO signalling, including regions within the temporal lobe".
The company said SNT-4728 was safe and well tolerated with no treatment related serious adverse events, with all observed adverse events either mild or moderate.
Syntara said further analyses was expected to be available by October 2026 and include "full clinical and imaging datasets, digital and biological markers".
The company said the availability of complete data from the study would further inform the conclusions drawn from the phase II exploratory study and enable a developmental path forward in the treatment of isolated REM sleep behavior disorder and the slowing of progression to Parkinson's disease.
Syntara was up 0.1 cents or 4.35 percent to 2.4 cents with 6.1 million shares traded.

ONCOSIL MEDICAL

Oncosil says data from 40 pancreatic cancer patients in its 'Tripp-FFX' trial showed the study met both primary endpoints of safety and local disease control.

Last year, Oncosil said it had recruited its 'Tripp-FFX' trial of its phosphorous-32 radiation device in combination with Folfirinox (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) chemotherapy for pancreatic cancer (BD: Jul 23, 2025).

In June, the company said its 88-patient, 'Tripp-FFX' trial met co-primary endpoints of safety and local disease control for pancreatic cancer, with 42 patients treated with Folfirinox alone and 40 patients treated with its device and Folfirinox (BD: Jun 9, 2026).

Today, Oncosil said the per-protocol analysis of the 40 patients treated with its device and Folfirinox chemotherapy showed a median overall survival of 21.3 months, compared to 15.6 months in patients treated with Folfirinox alone.

The company said there was "a 12.5 percent surgical resection rate, with 60 percent of resected Oncosil device-treated patients showing complete surgical removal of their cancer" compared to 7.3 percent and 33 percent in the Folfirinox only group, respectively.

Oncosil was up 10.5 cents or 10.7 percent to $1.09.

HUDSON INSTITUTE OF MEDICAL RESEARCH

The Hudson Institute says that removing the NLPR3 protein from epithelial cells can reduce silicosis, in mice, which may lead to the development of possible treatments.

The Hudson said silicosis was an incurable lung disease caused by inhaling silica dust, with cases increasing due to young tradespeople working with engineered stone.

The Institute said that the structural cells lining the airways, rather than immune cells, were "major instigators of silica-induced lung damage" and that the discovery identified "a new therapeutic target for a disease that currently has no cure".

The Hudson Institute said a study removed NLRP3 specifically from epithelial cells in wild-type mice and showed "early inflammation was dramatically reduced, recruitment of a damaging and persistent pro-fibrotic immune cell population was blocked [and] long-term lung damage and scarring were significantly decreased".

The Institute said the study provided "the strongest evidence yet that targeting the airway lining could halt disease progression, opening the door to precision therapies that could stop the disease before irreversible damage occurs".

The Institute said the study, titled 'Epithelial NLRP3 drives silica-induced lung injury and fibrosis through IL-18 and pro-fibrotic neutrophil recruitment' was in Particle and Fibre Toxicology at: https://link.springer.com/article/10.1186/s12989-026-00682-9.

RENERVE

Renerve says it has marketing approval for its Nervalign nerve cuff for peripheral nerve repair in Indonesia.

Last year, Renerve said the US Department of Defense and Veterans Affairs healthcare systems approved the use of its Nervalign nerve cuff (BD: Nov 13, 2025).

Today, the company said the approval opened "access to Southeast Asia's largest economy and one of the region's most significant addressable markets for nerve repair".

Renerve said Indonesia's demographic and clinical profile pointed "to substantial and growing demand for peripheral nerve repair solutions".

Renerve managing-director Dr Julian Chick said securing approval in Indonesia was "a significant milestone in our Asia-Pacific expansion strategy".

Renerve was up 0.1 cents or 1.25 percent to 8.1 cents.

NYRADA

Nyrada says it has dosed the first of up-to 150 patients in its phase IIa trial of Xolatryp, or NYR-BI03, for reducing myocardial injury in heart attack patients.

Last year, Nyrada said it had planned a 150-patient, double-blind, randomized, controlled, phase IIa trial of Xolatryp for cardio-protection in heart attack; and later, said that it had opened the first trial site (BD: Jul 23, 2025; Apr 22, 2026).

Last month, the company said it had pre-screened 20 patients but was yet to enrol a patient in the phase IIa trial, with completion still expected in 2027 (BD: Jun 16, 2026).

Today, Nyrada said that the patient would be followed for a further 30 days for safety and tolerability outcomes as well as efficacy measures, with trial site activation continuing at Perth's Sir Charles Gairdner Hospital in Perth.

The company said it was advancing approval for other sites in Australia and progressing expansion of the study to New Zealand; and expected final patient dosing in "mid-2027" and top-line results three months after the final patient's 30-day follow-up visit.

Nyrada was unchanged at 44 cents.

IMMURON

Immuron says Las Vegas, Nevada's Pullan Consulting will provide business development services to assist in securing a strategic partnership for IMM-529.

Last year, Immuron said it had US Food and Drug Administration investigational new drug approval for an up-to 60-patient, phase II trial of IMM-529 for Clostridioides difficile infection, expected to begin by July 2026 (BD: Nov 5, 2025).

Today, the company said it was seeking partners to advance IMM-529 under a licence, with the licensee to fund development, registration, and commercialization costs.

Immuron said historical Clostridioides difficile infection-focused licencing arrangements showed a range of possible transaction structures including up-front payments ranging from $US1 million to US50 million ($A1.4 million to $A72 million) and milestone payments ranging from $US25 million to $US570 million ($A36 million to $A822 million).

The company said "IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease".

Immuron said Pullan was "a highly regarded life sciences advisory firm with a strong track record of executing between five and 12 partnering transactions annually over the past 20 years".

Immuron said Pullan specialized in guiding companies through the partnering process, "from strategy development and partner identification to negotiation and transaction execution" and was expected to maximize the value of IMM-529.

Immuron was up 0.3 cents or 8.3 percent to 3.9 cents.

CONTROL BIONICS

Control Bionics says its extraordinary general meeting will vote to issue director Prof Nicholas Opie 1,250,000 options, exercisable at 6.3 cents each by May 13, 2031.

Earlier this year, Control Bionics said it appointed Prof Opie as a non-executive director, with Dr Stephanie Phillips to retire as a director (BD: May 14, 2026).

Today, the company said the options were in addition to Prof Opie's $51,700 yearly fees.

Control Bionics said investors would vote to ratify the prior issue of shares and issue placement shares to directors as well as 1,200,000 consultant shares; and the meeting would be at Level 3, 22 Market Street, Sydney on August 6, 2026 at 10am (AEST).

Control Bionics was up 0.1 cents or 1.35 percent to 7.5 cents.

RADIOPHARM THERANOSTICS

Radiopharm says it has received $5,885,131 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Radiopharm said the incentive related to research and development expenditure for the year to June 30, 2025, including $104,475 in interest.
The company said that the funds would be used to continue development of its portfolio of radio-pharmaceutical products for diagnostic and therapeutic applications.
Radiopharm was unchanged at two cents with 7.1 million shares traded.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics has told the ASX that it is not aware of any information it has not announced which, if known, could explain the recent trading in its securities.
The ASX said that Proteomics' share price rose 37.5 percent from a low of 16 cents on July 2 to a high of 22 cents on July 3, 2026, but did not note a significant increase in the number of shares traded.
The company said that "the recent increase in trading activity has occurred following the end of the financial year and may reflect broader market factors" but it was unable to identify any specific cause for the recent trading activity.
Proteomics fell 2.5 cents or 12.5 percent to 17.5 cents with 2.45 million shares traded.

CURVEBEAM A.I.

Curvebeam has requested a trading halt "pending an announcement … to the market in relation to an update in connection with a proposed capital raising".
Trading will resume on July 8, 2026, or on an earlier announcement.
Curvebeam last traded at 1.8 cents.

CONTROL BIONICS

Sydney's Phoenix Development Fund says its 70,194,769 holding in Control Bionics has been diluted in a share issue on December 8, 2025 from 17.4 percent to 16.19 percent.
Last year, Control Bionics said it raised $3.25 million at 6.5 cents a share, a 6.4 percent discount to the five-day volume weighted average price (BD: Dec 1, 2025).
Last month, the company said it had commitments to raise $9,500,000 at 7.5 cents a share in a placement, with a $500,000 share purchase plan to follow (BD: Jun 25, 2026).

AMPLIA THERAPEUTICS

Amplia says it has appointed Medicines Development for Global Health chief operating officer Brett Carter as a non-executive director, effective from today.
Amplia said Mr Carter had more than 25 years of experience in oncology drug development, had worked for Glaxosmithkline, been chief executive officer of the Cancer Therapeutics Cooperative Research Centre, where its drug assets were discovered as well as a director of Greywolf Therapeutics Australia.
The company said Mr Carter held a Bachelor of Science from the Royal Melbourne Institute of Technology and a Master of Business Administration from England's London Business School.
Amplia was unchanged at 15 cents with 1.5 million shares traded.

COMPUMEDICS

Compumedics says Chrisopher Barys has resigned as a non-executive director “by mutual agreement”, effective from June 30, 2025, as it “enters its next phase of development”.
Last year, Compumedics said it appointed the US-based Mr Barys as a non-executive director (BD: Sep 22, 2025).

CHIMERIC THERAPEUTICS

Chimeric says non-executive director Eric Sullivan has notified the board of his decision to retire from the board “for personal reasons”, effective immediately.
Last week, Chimeric said it appointed Hawkesbury Partners as independent financial advisors “to undertake a review of strategic options available” (BD: Jul 1, 2026).
Chimeric fell 0.2 cents or 3.45 percent to 5.6 cents.